Measurement of Pro-resolving Inflammation Biomarkers in Saliva, Gingival Fluid, and Dental Pulp in Patients With Symptomatic Pulpitis and Healthy Controls

Strategic Inflammation Modulation and Advanced Regenerative Therapy of Dental PULP

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07450235

Acronym

SMART-PULP

Enrollment

Registered

2026-03-04

Start date

2026-03-01

Completion date

2028-12-01

Last updated

2026-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Pulpitis

Brief summary

This observational study aims to better understand inflammation inside the dental pulp (the inner tissue of the tooth) in patients with symptomatic pulpitis compared with healthy individuals. Researchers will measure inflammation-related biomarkers in saliva, gingival fluid, and dental pulp samples to determine whether these substances reflect the level of inflammation. The study also evaluates whether saliva and oral fluids could be used as simple, non-invasive tools to detect and monitor pulp inflammation. We hypothesize that patients with pulpitis will show different biomarker levels compared with healthy controls.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Age ≥ 18 years, male or female. * Patient consulting for symptomatic pulpitis (confirmed clinical and radiographic diagnosis) or for wisdom tooth extraction (healthy subject). * Patient able to understand the research and having signed a written consent form. * Permanent teeth only.

Exclusion criteria

* Refusal to participate. * Pregnancy or breastfeeding. * Antibiotic or anti-inflammatory treatment in the week prior to sampling. * Clinically diagnosed inflammatory gingival or periodontal disease (gingivitis or periodontitis) * Chronic systemic inflammatory disease (e.g., uncontrolled diabetes, autoimmune diseases). * Patients under guardianship, conservatorship, or legal protection

Design outcomes

Primary

Measure	Time frame	Description
Measurement Compare LXA4 and RvE1 levels in saliva, gingival crevicular fluid, and dental pulp in patients with dental pulpitis and healthy subjects.	Day 0 (initial visit)	Average concentration of LXA4 and RvE1 (expressed in pg/mL or ng/mL) measured by mass spectrometry in each type of biological sample, compared between the pulpitis group and the healthy group.

Countries

France

Contacts

CONTACTAlexis Mr Gaudin, Professor

Alexis.Gaudin@univ-nantes.fr+33240412913

Outcome results